Oxford genetics secures $2m for bioproduction optimisation R&D

By Dan Stanton contact

- Last updated on GMT


Related tags: Dna

Oxford Genetics hopes to provide improved bioinformatics in order to optimise mammalian bioproduction through a £1.6m grant.

The £1.61m ($2m) grant from Innovate UK was secured by Oxford genetics in order to undertake a research project exploring computational and synthetic biology approaches for optimising mammalian biomanufacturing processes.

“The production yields of many biological drugs are often very low, or at least unpredictable or variable,”​ CEO Ryan Cawood told Biopharma-Reporter.com. “For this reason by using statistical analysis to try and remove any uncertainty by designing proteins, viruses and cells better we can reduce these challenges.”

The funding will be spent primarily on internal research over a three year period, done in collaboration with the University of Oxford.

“The grant aims to deliver services to our biopharmaceutical clients by providing improved bioinformatics and software, coupled with a range of in house tools that we can help to deliver consistency and high productivity in the services we provide,”​ Cawood said. 

The news comes a month after Oxford Genetics secured a $1m grant​ – also from Innovate UK – to conduct research into increasing the efficiency and reducing the cost of scaling-up viral vector production.

Related news

Show more

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 21-May-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more